Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
-
date post
21-Dec-2015 -
Category
Documents
-
view
222 -
download
1
Transcript of Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
Management of Management of
Rheumatoid arthritis, Rheumatoid arthritis,
Osteoarthritis & GoutOsteoarthritis & Gout
Dr. Eoin Casey MD FRCPI, Dr. Eoin Casey MD FRCPI, FRCPFRCP
Background ReadingBackground Reading
Davidson’s Principles & Practice of Medicine, Davidson’s Principles & Practice of Medicine,
5050thth Anniversary Ed, 2002 Anniversary Ed, 2002
Musculoskeletal disorders, Ch 20: pg 957-1047Musculoskeletal disorders, Ch 20: pg 957-1047
Clinical Assessment of the Musculoskeletal Clinical Assessment of the Musculoskeletal
System (handbook) Arthritis and Rheumatism System (handbook) Arthritis and Rheumatism
Council UKCouncil UK
http://www.arc.org.uk/about_arth/opubs/6321/6321.pdfhttp://www.arc.org.uk/about_arth/opubs/6321/6321.pdf
General AssessmentGeneral Assessment
HistoryHistory Clinical examinationClinical examination Functional anatomyFunctional anatomy PhysiologyPhysiology InvestigationsInvestigations Major manifestations of Major manifestations of
musculoskeletal diseasemusculoskeletal disease
Symptoms & SignsSymptoms & Signs
Joint painJoint pain StiffnessStiffness SwellingSwelling InflammationInflammation Skin changesSkin changes Muscle changesMuscle changes DeformityDeformity Non-specific systemic symptomsNon-specific systemic symptoms (weight(weight↓; appetite↓; energy ↓; concentration ↓; mood ↓; appetite↓; energy ↓; concentration ↓; mood
↓)↓)
Aims of managementAims of management
Educate the patientEducate the patient
Control painControl pain
Optimise functionOptimise function
Beneficially modify the disease Beneficially modify the disease
processprocess
““It is much more important to It is much more important to
know what sort of a patient know what sort of a patient
has a disease than what sort has a disease than what sort
of a disease a patient has.”of a disease a patient has.”
William Osler 1849-1919William Osler 1849-1919
Management of OAManagement of OA
Patient’s personalityPatient’s personality
AttitudeAttitude
Holistic factorsHolistic factors
- activities of daily living- activities of daily living
- co-morbid disease- co-morbid disease
Availability, cost & logistics of evidence-Availability, cost & logistics of evidence-
based interventionbased intervention
Patient educationPatient education
Randomized controlled trials have Randomized controlled trials have
shown that education results in shown that education results in
substantial improvement and substantial improvement and
prolonged benefitprolonged benefit
Management of OAManagement of OA
ExerciseExercise - aerobic fitness- aerobic fitness
- local strengthening exercises- local strengthening exercises
Weight reductionWeight reduction Simple analgesiaSimple analgesia
- eg Paracetamol 1g 4-6 hrly- eg Paracetamol 1g 4-6 hrly
Non-steroidal anti-inflammatory drugsNon-steroidal anti-inflammatory drugs
- - (NSAIDS)(NSAIDS)
NSAIDSNSAIDS
>40 NSAIDS available in Ireland>40 NSAIDS available in Ireland Top most prescribed drugs in the worldTop most prescribed drugs in the world In favour of their use areIn favour of their use are - effectiveness- effectiveness - lack of toxicity- lack of toxicity - affordability- affordability Variable individual tolerance and responseVariable individual tolerance and response Non-responders to one agent may Non-responders to one agent may
improve with anotherimprove with another
NSAIDSNSAIDS
Mechanism of ActionMechanism of Action
- - ↓ prostaglandin levels↓ prostaglandin levels
- inhibit cyclooxygenase (COX)- inhibit cyclooxygenase (COX)
Cyclo-oxygenase Cyclo-oxygenase isoformsisoforms
COX I COX I - - housekeeping enzymehousekeeping enzyme - expressed in gastric - expressed in gastric
mucosa, platelets & kidneymucosa, platelets & kidney
COX II COX II - - inflammatory enzymeinflammatory enzyme
- expressed in various - expressed in various tissues largely at sites of tissues largely at sites of inflammationinflammation
Gastric side effects of Gastric side effects of NSAIDSNSAIDS
GIT toxicity - up to 30%GIT toxicity - up to 30%
Aetiological factor in 30% gastric Aetiological factor in 30% gastric
ulcersulcers
10% of RA/OA patients hospitalised 10% of RA/OA patients hospitalised
annually for NSAID associated annually for NSAID associated
bleedingbleeding
Endoscopic evidence of ulceration in Endoscopic evidence of ulceration in
20% of NSAID users even in absence 20% of NSAID users even in absence
of symptomsof symptoms
2000 deaths per annum in UK2000 deaths per annum in UK
Risk factors for NSAID Risk factors for NSAID gastritisgastritis
Age > 60 yearsAge > 60 years
Past history of PUDPast history of PUD
Past history of adverse effects with NSAIDSPast history of adverse effects with NSAIDS
Steroid useSteroid use
High dosesHigh doses
Multiple NSAIDSMultiple NSAIDS
Specific NSAIDS eg Indomethacin, AzapropazoneSpecific NSAIDS eg Indomethacin, Azapropazone
↓↓riskrisk - - Proton pump inhibitors; RanitidineProton pump inhibitors; Ranitidine
Cyto-protection with MesoprostilCyto-protection with Mesoprostil
NSAIDS side effectsNSAIDS side effects
Older people are at greatest risk Older people are at greatest risk for for
- renal- renal
- cardiovascular- cardiovascular
- GIT toxicity- GIT toxicity
Other treatment Other treatment modalitiesmodalities
Nutri-pharmaceuticalsNutri-pharmaceuticals
- Glucosamine- Glucosamine
- Chondroitin Sulphate- Chondroitin Sulphate
Topical agentsTopical agents
PhysiotherapyPhysiotherapy
Occupational therapyOccupational therapy
Approach to Approach to managementmanagement
Holistic approach to assessmentHolistic approach to assessment
Education is as important as Education is as important as
medicationsmedications
NSAIDS NSAIDS
CorticosteroidsCorticosteroids
Disease modifying agents (slow acting)Disease modifying agents (slow acting)
Steroids in Rheumatoid Steroids in Rheumatoid ArthritisArthritis
Glucocorticoids in low doses <7.5mg Glucocorticoids in low doses <7.5mg
daily are very effective to bridge the daily are very effective to bridge the
gap of the latent period before gap of the latent period before
disease modifying drugs workdisease modifying drugs work
Local intra-articular steroid injectionsLocal intra-articular steroid injections
Disease modifying Disease modifying agentsagents HydroxychloroquineHydroxychloroquine SalazopyrineSalazopyrine PenicillaminePenicillamine GoldGold MethotrexateMethotrexate AzathioprineAzathioprine LuflunomideLuflunomide Cyclophosphamide, CyclosporineCyclophosphamide, Cyclosporine Anti TNF agents Anti TNF agents eg Adalimumab (Humira), Etanercept (Embrel), Infliximabeg Adalimumab (Humira), Etanercept (Embrel), Infliximab
Non-drug treatmentsNon-drug treatments
PhysiotherapyPhysiotherapy
Physical treatmentsPhysical treatments
SurgerySurgery
Coping strategiesCoping strategies
GoutGout
Crystal depositionCrystal deposition
Negatively bi-refringent sodium monouric Negatively bi-refringent sodium monouric
crystals in joints, bursa, tendons and crystals in joints, bursa, tendons and
kidneykidney
Not always associated with hyperuricaemia Not always associated with hyperuricaemia
Stages of GoutStages of Gout
1. Acute Gout1. Acute Gout
2. Inter critical periods2. Inter critical periods
3. Chronic tophaceous Gout3. Chronic tophaceous Gout
Treatment of acute Treatment of acute attackattack
One of the most painful One of the most painful
conditions knownconditions known
NSAIDSNSAIDS
Colchicine (main s/e diarrhoea)Colchicine (main s/e diarrhoea)
SteroidsSteroids
Long term Long term managementmanagement Uricosuric agents Uricosuric agents
- Allopurinol 100mg od increasing to 300mg - Allopurinol 100mg od increasing to 300mg odod
- MOA: Xanthine oxidase inhibitor- MOA: Xanthine oxidase inhibitor
- 2-3 weeks after acute attack- 2-3 weeks after acute attack
- initiation may precipitate an acute attack- initiation may precipitate an acute attack